A. Basiorka

发表

Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858

Sheng Wei, K. Heider, J. Lancet, 2017, Leukemia.

Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS

P. Ji, A. List, J. Yang, 2017, Leukemia.

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes

F. Solé, A. Karsan, T. Haferlach, 2015, Blood Cancer Journal.

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients

Larry J. Smith, Sheng Wei, R. Wells, 2013, Proceedings of the National Academy of Sciences.

Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

J. Tavernier, Sheng Wei, G. Reuther, 2016, Cancer research.

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

Sheng Wei, J. Maciejewski, P. Fenaux, 2017, Haematologica.

The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

J. Cleveland, Sheng Wei, T. Cluzeau, 2016, Blood.

The Proinflammatory Protein S100A9 Suppresses Erythropoietin Elaboration in Patients with Myelodysplastic Syndromes

G. Mufti, Sheng Wei, J. Maciejewski, 2015 .

Targeted Repression of TP53 Promotes Erythropoiesis in Del(5q) MDS and Overcomes Clinical Resistance to Lenalidomide

Larry J. Smith, Sheng Wei, R. Wells, 2012 .

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors

Sheng Wei, E. Padron, L. Sokol, 2014, PloS one.

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes

F. Solé, J. Maciejewski, T. Cluzeau, 2015, Oncotarget.

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

P. Fenaux, Chen Wang, J. Lancet, 2021, Haematologica.

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

B. Fridley, Sheng Wei, P. Fenaux, 2018, The Lancet. Haematology.

Inflammaging-Associated Metabolic Alterations Foster Development of the MDS Genotype

Sheng Wei, T. Cluzeau, E. Padron, 2015 .

Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.

David A. Williams, A. Verma, M. Schipma, 2014, Blood.

Changing the Pathobiological Paradigm in Myelodysplastic Syndromes: The NLRP3 Inflammasome Drives the MDS Phenotype

A. Basiorka, 2017 .

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype

T. Cluzeau, A. List, D. Sallman, 2016, Front. Oncol..

Aberrant overexpression of CD 14 on granulocytes sensitizes the innate immune response in mDia 1 heterozygous del ( 5 q ) MDS

David A. Williams, A. Verma, M. Schipma, 2014 .

32 ACTIVATION OF REDOX-SENSITIVE INFLAMMASOMES UNDERLIES THE BIOLOGICAL PHENOTYPE OF MYELODYSPLASTIC SYNDROMES

Sheng Wei, M. Cooper, E. Padron, 2015 .

Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858

K. Anderson, Sheng Wei, M. Friedrich, 2017, Leukemia.

Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

J. Tavernier, Sheng Wei, G. Reuther, 2016, Cancer research.